News News November, 2019 IGM Biosciences to Present at Three Upcoming Investor Conferences Read More... November, 2019 IGM Biosciences Announces Third Quarter 2019 Financial Results Read More... October, 2019 IGM Biosciences Initiates First-in-Human Phase 1 Clinical Trial of IGM-2323 for the Treatment of Relapsed/Refractory B Cell Non-Hodgkin’s Lymphoma Read More... September, 2019 IGM Biosciences Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares Read More... September, 2019 IGM Biosciences Announces Pricing of Initial Public Offering Read More... July, 2019 IGM Biosciences Announces $102 Million Series C Financing to Advance its IgM Antibody Platform and Pipeline Read More... January, 2019 IGM Biosciences Appoints M. Kathleen Behrens, Ph.D., to Board of Directors Read More... January, 2019 IGM Biosciences Appoints Misbah Tahir as Chief Financial Officer Read More... November, 2018 IGM Biosciences Appoints Wayne Godfrey, M.D., as Vice President, Clinical Development Read More... August, 2018 IGM Biosciences Appoints Julie Hambleton, M.D., to Board of Directors Read More... « Previous 1 2 3 Next »
